Search

Search Constraints

You searched for: Author/Creator Gadaud, Noémie

Search Results

1. "Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies. Issue 4 (8th March 2022)

2. Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study. Issue 6 (12th May 2022)

3. More than ten percent of relapses occur after five years in AML patients with NPM1 mutation. Issue 5 (15th April 2020)

4. Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. (June 2019)

5. Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors. Issue 2 (28th January 2020)